| Name | Title | Contact Details |
|---|
Aspen Laser Systems is redefining pain management and recovery with our high intensity, class IV laser therapy devices. With over 30 years of experience, Aspen Laser delivers quality products and long-lasting results for your patients.
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
Vision Innovation Partners unites the mid-Atlantic’s premier ophthalmology practices and surgery centers through good people, expert leadership, the sharing of best practices and the backing of a leading middle-market private equity firm.
Germiphene Corporation is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Embecta will be the name of the independent, publicly-traded company that will hold BD`s Diabetes Care business